Abingworth LLP Crispr Therapeutics Ag Transaction History

Abingworth LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Mar 01, 2021	SELL	$79.67 - $173.23 $20.7 Million - $45 Million	-259,599 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $20.4 Million - $26.1 Million	-259,599 Reduced 50.0%	259,599 $21.7 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $4.01 Million - $7.99 Million	-109,200 Reduced 17.38%	519,198 $31.6 Million
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $22.3 Million - $28.5 Million	-542,870 Reduced 46.35%	628,398 $25.7 Million
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $1.5 Million - $2.79 Million	-65,934 Reduced 5.33%	1,171,268 $33.5 Million
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $27.7 Million - $47.8 Million	-650,000 Reduced 34.44%	1,237,202 $72.7 Million
Q1 2018 May 15, 2018	SELL	$23.52 - $58.17 $1.51 Million - $3.73 Million	-64,157 Reduced 3.29%	1,887,202 $86.2 Million
Q4 2017 Feb 14, 2018	SELL	$16.95 - $23.48 $348,288 - $482,467	-20,548 Reduced 1.04%	1,951,359 $45.8 Million
Q3 2017 Nov 14, 2017	BUY	$16.75 - $20.66 $33 Million - $40.7 Million	1,971,907	1,971,907 $35.1 Million

505

57.3M

1.74M

1.84M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.95B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

Stay updated on Abingworth LLP with notifications on news.